Replimune Group, Inc.: Form 10-Q for the period ended Dec 31, 2022
Filed with the SEC on Feb 9, 2023 and accepted by EDGAR at Feb 9, 2023, 08:17 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2022-10-01 to 2022-12-31 | $30.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2022-04-01 to 2022-12-31 | $88.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2022-10-01 to 2022-12-31 | −$41.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-04-01 to 2022-12-31 | −$124.1m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2022-10-01 to 2022-12-31 | −$39.7m | us-gaap:NetIncomeLoss |
| Net income | 9 months2022-04-01 to 2022-12-31 | −$125.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-10-01 to 2022-12-31 | −$0.69 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2022-04-01 to 2022-12-31 | −$2.25 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-10-01 to 2022-12-31 | −$0.69 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2022-04-01 to 2022-12-31 | −$2.25 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-10-01 to 2022-12-31 | 57,857,132 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2022-04-01 to 2022-12-31 | 55,618,052 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2022-04-01 to 2022-12-31 | −$95.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2022-04-01 to 2022-12-31 | $2.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-12-31 | $206.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-12-31 | $624.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-12-31 | $678.5m | us-gaap:Assets |
| Current liabilities | At period end2022-12-31 | $26.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-12-31 | $83.2m | us-gaap:Liabilities |
| Long-term debt | At period end2022-12-31 | $28.4m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2022-12-31 | $595.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001737953-23-000005. Last ingested by Listed: Nov 10, 2026, 04:35 ET. Listed shows no prices and gives no investment advice.